載入中
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
一般交易時段
US$1.495
−US$0.015 · -0.99%
盤中時間採用ET。市場資料可能有所延遲。
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
日內區間
目前US$1.495
52週區間
目前US$1.495
盤中時間採用ET。市場資料可能有所延遲。
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
日內區間
目前US$1.495
52週區間
目前US$1.495
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 3759.2萬 USD | 4183.8萬 USD | 4371.7萬 USD | 3791.6萬 USD | 3298.4萬 USD |
| 銷售、一般及管理費用 | 1381.6萬 USD | 1103.9萬 USD | 1204.6萬 USD | 1307萬 USD | 901.8萬 USD |
| 營業費用 | 5140.8萬 USD | 5287.7萬 USD | 5576.3萬 USD | 5098.6萬 USD | 4200.2萬 USD |
| 利息收入 | 467.8萬 USD | 732萬 USD | 651.9萬 USD | 94.7萬 USD | 2.6萬 USD |
| 利息支出 | — | — | 96.4萬 USD | — | — |
| 營業利益 | −5140.8萬 USD | −5287.7萬 USD | −5576.3萬 USD | −5098.6萬 USD | −4200.2萬 USD |
| 淨利 | −4637.7萬 USD | −4300.2萬 USD | −4750.5萬 USD | −4797.8萬 USD | −3790.9萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2015年10月7日 | 1:4 | — | — |
已生效 2015年10月7日
1:4
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI819.12萬0.00%2.3兆 USD0.03%US$380.44-0.30%
iShares Russell 2000 ETFIWM363.4萬0.00%787.4億 USD0.19%US$275.91-0.72%
Vanguard Extended Market ETFVXF302.91萬0.00%954億 USD0.05%US$231.58-0.83%
Vanguard Russell 2000 ETFVTWO148.21萬0.01%180億 USD0.06%US$111.44-0.74%
iShares Russell 2000 Value ETFIWN110.59萬0.01%137.49億 USD0.24%US$210.36-0.35%
iShares Biotechnology ETFIBB105.28萬0.01%108.2億 USD0.44%US$201.22-1.49%
Vanguard Health Care ETFVHT75.72萬0.00%220億 USD0.09%US$316.99-1.15%
Schwab U.S. Small-Cap ETFSCHA74.04萬0.00%217.13億 USD0.03%US$32.43-0.70%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBVanguard Health Care ETFVHTSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
